Chimeric antigen receptor T-cell therapy offers significant hope for refractory hematological malignancies. However, clinicians often worry about brain vulnerability when treating secondary and primary central nervous system lymphomas. Investigating CAR T-cell neurocognitive outcomes has therefore become a critical priority for neuro-oncology teams. A landmark study from Pitié-Salpêtrière Hospital now provides essential clarity on medium-term cognitive evolution.

Baseline Cognitive Vulnerability in Patients With CNS Lymphoma

Patients who present with isolated central nervous system lymphomas carry substantial pre-existing neurological damage. Prior high-dose methotrexate chemotherapy, whole-brain radiation, and focal parenchymal lesions impair baseline cognitive functioning. In this cohort, baseline neuropsychological evaluation showed a median Montreal Cognitive Assessment score of only 23.5 points. Furthermore, between 34% and 80% of patients exhibited overt abnormalities across major cognitive domains prior to cellular infusion. These domains included verbal memory, executive functioning, processing speed, visuospatial integration, and expressive language. Therefore, clinicians must recognize that baseline impairment reflects disease biology rather than imminent cellular therapy failure. Early neuropsychological documentation provides an indispensable benchmark for post-treatment monitoring. Without objective pre-infusion metrics, clinicians might wrongly attribute pre-existing deficits to emerging cellular complications. Consequently, comprehensive pre-treatment profiling ensures accurate interpretation of subsequent recovery trajectories.

Acute Neurotoxicity and Early MoCA Trajectories

Immune effector cell-associated neurotoxicity syndrome remains a major clinical challenge following cellular infusion. In this study, 63% of patients developed acute neurotoxicity, and 20% experienced severe grade 3 or higher events. Consequently, early cognitive evaluations at week six revealed divergent clinical pathways across the patient cohort. Specifically, 70% of individuals maintained or improved their MoCA scores compared to their pre-treatment baseline. Conversely, 30% of patients experienced measurable cognitive decline during this immediate post-infusion window. Statistical analysis confirmed that acute neurotoxicity severity significantly drove these early divergent trajectories. Patients experiencing high-grade neurotoxicity suffered pronounced short-term drops in processing speed and executive performance. However, aggressive supportive management with corticosteroids and anti-cytokine agents successfully contained persistent inflammation. Thus, early cognitive decline primarily represents transient immunologic disruption rather than irreversible structural damage.

Evaluating Medium-Term CAR T-Cell Neurocognitive Outcomes

Longitudinal neuropsychological follow-up revealed remarkable medium-term CAR T-cell neurocognitive outcomes among surviving patients. By month six, patient MoCA scores improved significantly from a baseline of 22.6 to a mean of 24.7 points. Moreover, this cognitive improvement continued through the twelve-month assessment, reaching a mean score of 25.4 points. Therefore, even patients who experienced initial week-six deterioration demonstrated notable neurocognitive recovery over time. Sustained tumor control appears to permit endogenous neural plasticity and restorative functional reorganization. In addition, resolving secondary neuroinflammation facilitates progressive cognitive compensation across multiple cerebral networks. Patients exhibited meaningful gains in executive functioning, functional independence, and working memory performance. These findings offer immense clinical reassurance to neuro-oncologists, hematologists, and patients alike. Hence, acute neurotoxicity does not inherently preclude robust medium-term neurocognitive rehabilitation.

Mechanisms of Neural Repair and Reversible Dysfunction

Understanding the cellular mechanisms driving cognitive restoration helps oncologists optimize post-infusion rehabilitation protocols. The early drop in MoCA performance stems from intense microglial activation and systemic cytokine elevation. Circulating cytokines disrupt blood-brain barrier integrity and trigger transient subcortical axonal dysfunction. Fortunately, prompt immunomodulatory therapy and subsequent immune homeostatic recalibration suppress persistent neurotoxic signaling. Once malignant lymphocytes clear and perivascular inflammation subsides, cerebral repair mechanisms actively proceed. Oligodendrocyte precursors promote remyelination, while surviving neural pathways re-establish synaptic transmission. Furthermore, the absence of active lymphomatous mass effect relieves parenchymal compression and normalizes local perfusion. Clinicians must therefore view post-CAR cognitive impairment as a largely reversible functional disturbance. Consequently, structured cognitive rehabilitation during the subacute phase can significantly enhance long-term functional autonomy.

Optimizing Clinical Practice and Follow-Up Protocols

These cognitive findings underscore the need for structured long-term survivorship care in neuro-oncology programs. First, multidisciplinary teams should integrate serial MoCA testing into standard post-infusion outpatient visits. Specifically, scheduling evaluations at baseline, week six, month six, and month twelve captures decisive trajectory inflections. Second, physicians should reassure anxious patients and caregivers when early post-treatment scores drop. Because most patients rebound by month six, clinicians can avoid prematurely discontinuing supportive survivorship pathways. Third, centers must establish dedicated neuro-rehabilitation referrals for patients suffering severe acute neurotoxicity. Speech-language pathologists and occupational therapists provide vital strategies that accelerate executive and memory recovery. In addition, continuing tight surveillance for tumor recurrence remains imperative throughout follow-up. Integrating standardized cognitive metrics ensures comprehensive, compassionate, and evidence-based patient management.

Frequently Asked Questions

What baseline cognitive deficits are common in CNS lymphoma before CAR T-cell therapy?

Patients with central nervous system lymphoma frequently experience significant baseline cognitive deficits before receiving cellular immunotherapy. Tumoral parenchymal invasion, previous high-dose chemotherapy, and prior radiation therapy often induce substantial damage. Consequently, up to 80% of individuals display abnormal baseline performance in executive function, verbal memory, visuospatial skills, and mental processing speed.

Does acute neurotoxicity permanently impair long-term cognitive function in these patients?

Acute neurotoxicity does not necessarily lead to permanent cognitive impairment in central nervous system lymphoma patients. Although severe acute neurotoxicity correlates strongly with cognitive drops at six weeks, long-term outcomes remain remarkably favorable. Most patients experience sustained, statistically significant cognitive improvement by months six and twelve as neuroinflammation subsides.

How should clinical teams monitor cognitive function following CAR T-cell infusion?

Clinical teams should implement structured, standardized neuropsychological assessments across routine outpatient visits. Utilizing validated tools like the Montreal Cognitive Assessment provides rapid, reproducible scoring. Clinicians should evaluate patients prior to lymphodepletion, at six weeks, six months, and twelve months post-infusion to identify emerging deficits and guide rehabilitation.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Mersali S et al. Medium-Term Cognitive Outcome in Patients With CNS Lymphomas Treated With Chimeric Antigen Receptor T-Cell Therapy. Neurology. 2026 Oct 27. doi: 10.1212/WNL.0000000000218561. PMID: 42826379.

Hernández-Tost S, et al. Neurotoxicity in patients with CNS lymphomas treated with CAR T-cell therapy. J Immunother Cancer. 2025;13(4):e009412.

Barata A, Johnson PC, et al. Long-term cognitive outcomes in adult patients receiving chimeric antigen receptor T-cell therapies. Transplant Cell Ther. 2025;31(4):236.e1-236.e13.